Daniella Magen
Haifa, HA, Israel
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 55 publications
Profile of a pediatric hypertensive cohort in a tertiary referral center.
Journal: Journal of nephrology
Published: February 05, 2026
Temporary mycophenolate discontinuation and reintroduction in pediatric kidney transplantation: predictors and long-term outcomes.
Journal: Pediatric nephrology (Berlin, Germany)
Published: January 11, 2026
Natural History of Advanced Primary Hyperoxaluria Type 1: A Retrospective Study.
Journal: Kidney medicine
Published: November 10, 2025
Navigating complex clinical decisions: kidney transplantation following abdominal aorto-aortic bypass in infantile Takayasu arteritis.
Journal: Pediatric nephrology (Berlin, Germany)
Published: June 17, 2025
IKAROS Associated Immunodeficiency and Thrombotic Thrombocytopenic Purpura.
Journal: Pediatric blood & cancer
Published: May 27, 2025
Expanded CRB2-related disease phenotype: multisystem involvement and post-transplant complications in monozygotic twins.
Journal: Pediatric nephrology (Berlin, Germany)
Published: February 10, 2025
Subcutaneous ofatumumab in recurrent focal segmental glomerulosclerosis after kidney transplantation.
Journal: Clinical kidney journal
Published: August 11, 2024
Long-term lumasiran therapy final results from a Phase 2 open-label extension study in primary hyperoxaluria.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: August 08, 2024
PDSS1 mutations-associated steroid-resistant nephrotic syndrome: case report and review of literature.
Journal: Pediatric nephrology (Berlin, Germany)
Published: June 26, 2024
Prevention of post-transplant lymphoproliferative disorder in pediatric kidney transplant recipients.
Journal: Pediatric nephrology (Berlin, Germany)
Published: June 13, 2024
Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-up of the Phase 3 ILLUMINATE-C Trial.
Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation
Published: March 26, 2024
Last Updated: 09/26/2026